Monte Rosa Therapeutics (GLUE) Net Income (2020 - 2026)

Monte Rosa Therapeutics' Net Income history runs 7 years deep, the most recent figure standing at -$44.6 million for Q1 2026.

• On a quarterly basis, Net Income fell 195.02% year-over-year to -$44.6 million in Q1 2026; TTM through Mar 2026 was -$113.4 million, a 583.65% decrease from a year earlier, with the FY2025 full-year figure at -$22.0 million, up 60.33% from the prior year.
• Net Income fell to -$44.6 million in Q1 2026 per GLUE's latest filing, from -$29.5 million in the prior quarter.
• Across five years, Net Income topped out at $46.9 million in Q1 2025 and bottomed at -$64.8 million in Q1 2022.
• The 5-year median for Net Income is -$30.3 million (2024), against an average of -$23.9 million.
• Across the five-year window, Net Income sank 463.48% in 2022 and surged 246.58% in 2025, its largest moves.
• Year by year, Net Income stood at -$30.8 million in 2022, then decreased by 8.02% to -$33.3 million in 2023, then surged by 192.43% to $30.7 million in 2024, then tumbled by 195.95% to -$29.5 million in 2025, then slumped by 51.08% to -$44.6 million in 2026.
• Per Business Quant, the three latest GLUE Net Income figures stand at -$44.6 million (Q1 2026), -$29.5 million (Q4 2025), and -$27.1 million (Q3 2025).